Randomized trial · people

Semaglutide 2.4 mg: 9.6% weight loss at 68 weeks in STEP 2

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In people with type 2 diabetes, weekly semaglutide 2.4 mg led to more weight loss than placebo over 68 weeks, and stomach and gut side effects were more common on the drug.

Kind
Randomized trial
Studied in
People
Number studied
1210
Published
2021
Journal
Lancet

What they tested

Does weekly semaglutide 2.4 mg help adults with overweight or obesity and type 2 diabetes lose more weight than placebo, and how does it compare on safety with the 1.0 mg dose?

How the study was done

A randomized, double-blind, placebo-controlled phase 3 trial in 1210 adults with a BMI (body-mass index, weight relative to height) of at least 27 kg/m2 and type 2 diabetes, run at 149 clinics in 12 countries. Participants got a weekly shot of semaglutide 2.4 mg, semaglutide 1.0 mg or placebo (a dummy shot) for 68 weeks, and everyone also followed a lifestyle program.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking semaglutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

By week 68, the 2.4 mg arm had lost an estimated 9.6% of body weight versus 3.4% for placebo, a gap of 6.2 percentage points. A 5% or greater weight drop was reached by 68.8% of the 2.4 mg arm and 28.5% of the placebo arm. Any adverse event was logged in 87.6% of the 2.4 mg arm, 81.8% of the 1.0 mg arm and 76.9% of the placebo arm. Digestive complaints, which were largely mild or moderate, showed up in 63.5% of the 2.4 mg arm, 57.5% of the 1.0 mg arm and 34.3% of the placebo arm.

What it doesn’t show

The trial included only adults with type 2 diabetes and a BMI of at least 27, all of whom also followed a lifestyle program, and it ran for 68 weeks, so it doesn't show what happens over a longer time. It was funded by Novo Nordisk.

The paper

Davies et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.

The compound

More studies on Semaglutide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking semaglutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo